Kennedy believes that vaccines cause autism and wants to use his perch to carry out further testing.
Currently, only 21% of Wall Street analysts have Palantir ranked a "buy". This makes Palantir the lowest recommended, best ...
Fintel reports that on November 14, 2024, Citigroup initiated coverage of Amgen (NasdaqGS:AMGN) with a Neutral recommendation ...
Analysts have set 12-month price targets for Amgen, revealing an average target of $349.0, a high estimate of $405.00, and a ...
Shares of pharmaceutical giant Amgen (AMGN) are attempting to bounce back after suffering a steep drop of 7.1% yesterday.
Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone mineral density, a ...
In a report released today, Yaron Werber from TD Cowen maintained a Buy rating on Amgen (AMGN – Research Report), with a price target of $383.00. The company’s shares closed yesterday at $298.84.
However, on the same day, Jefferies maintained a Buy rating on Amgen (NASDAQ: AMGN). Based on Amgen’s latest earnings release for the quarter ending September 30, the company reported a quarterly ...
As an aside, in the tech space, see What’s Happening With Snap Stock? Although the recent Amgen update didn’t bode well with ...
U.S. stock index futures on Wednesday pointed to a higher open, after the latest consumer inflation report came in-line with ...
Amgen (AMGN) stock spiked after the company ruled out out bone density concerns linked to obesity drug MariTide, following a ...